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This study estimated lifetime cost of treatment for patients in the United Kingdom (UK) presenting with stage IV breast cancer. To
determine patterns of treatment and resource use in the absence of direct observational data, a cancer physician panel was surveyed.
The survey questionnaire described four predefined treatment phases: active treatment; follow-up after active treatment until disease
progression; active supportive care after progression; and end-of-life care. Physicians were asked their major treatment strategies for
each phase. Monthly cost and average lifetime cost per patient were calculated. Only five cancer registries in the UK document the
proportion of breast cancer patients diagnosed with stage IV disease. Their data was used to estimate the incidence of metastatic
breast cancer at presentation throughout the UK. This value, together with lifetime cost per patient and projected survival time,
allowed approximation of the overall cost for this population of cancer patients in the UK. Annual incidence of stage IV breast cancer
at presentation in the UK is approximately 2100; according to treatment practice in 2002, lifetime cost per patient is d12500 and
total population cost is approximately d26 million. The substantial economic burden associated with patients diagnosed with
metastatic breast cancer should be considered when developing strategies for reducing its incidence such as increased awareness,
screening and preventative measures.
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Female breast cancer caused more than 12000 deaths in the United
Kingdom (UK) in the year 2000 (Cancer Research UK, 2002); in
1998, it was the leading cause of death among women aged 35–54
years (NICE, 2002a). During 1998, there were 32908 new
registrations of female breast cancer in England (Office for
National Statistics, 1998).
Breast cancer is staged according to tumour size and degree of
local spread, involvement of nearby lymph nodes, and the presence
of metastases. A stage IV breast cancer (advanced breast cancer) is
one that has metastasised and as such is considered incurable.
Common sites of metastasis include the lung, liver, bone, and brain
(American Cancer Society, 2003). The variability of its natural
history and clinical presentation poses a challenge to any attempt
to model its management.
The incidence and prevalence of metastatic breast cancer and its
associated morbidity and mortality involve a substantial economic
burden. Treatment of stage IV breast cancer is complex, and a
number of advances have occurred in the UK in recent years,
including the introduction of aromatase inhibitors, taxanes, and
trastuzumab. Earlier cost-of-illness studies or studies modelling
resource use in metastatic breast cancer (Richards et al, 1993;
Wolstenholme et al, 1998; Dolan et al, 1999) may not accurately
reflect current treatment patterns. The study described in this
paper was designed to investigate the current treatment patterns
associated with stage IV breast cancer in the UK and to estimate
the economic burden associated with those patients presenting
with an advanced stage of the disease.
METHODS
Study design
Cost-of-illness studies can be undertaken according to the
prevalence approach or the incidence approach. The prevalence
approach estimates the total cost of disease in a given year; the
incidence approach estimates the lifetime cost of cases first
diagnosed in a given year. The incidence approach is more useful
for the evaluation of healthcare options in a given time period, as it
provides a baseline against which new interventions can be
assessed (Drummond, 1992). The study reported here was
designed in accordance with the incidence approach to estimate
the lifetime cost of treatment for all female patients in the UK
with stage IV disease at first diagnosis of breast cancer. Databases
analysed included UK breast cancer data from 1994 to 2001.
Results were based on estimated incidence of the disease,
typical treatment patterns (as determined by members of a cancer
physician panel), estimated resource use and the respective
standard costs, average length of treatment, and average
survival time.
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The National Cancer Intelligence Centre at the Office of National
Statistics confirmed that no reliable, centrally held information on
the separate incidence of each stage of breast cancer in the UK
exists. Therefore, in order to estimate the annual incidence of stage
IV at presentation breast cancer for this study, we contacted the
regional cancer registries (see Appendix). Four English cancer
registries (Northern & Yorkshire, East Anglia, Thames (London
region), and West Midlands) and the Scottish Cancer registry were
able to provide information on breast cancer incidence according
to cancer stage. The expected proportion of stage IV cases among
all breast cancers at diagnosis was calculated as the average
proportion for these five registries, weighted by the total number
of registrations at each registry. The total incidence of breast
cancer (all stages) in England (Office for National Statistics, 1998),
Wales (Office for National Statistics, 1999), and Northern Ireland
(Office for National Statistics, 1999) was obtained from the Office
for National Statistics; the total incidence in Scotland was provided
by the Scottish Cancer Registry (Scottish Cancer Registry, 1998).
Published information on survival time of women with
metastatic breast cancer is scarce; survival information used in
this study was obtained from the Royal Marsden Hospital database
in London. The dataset includes staging information for 2353
female patients seen at Royal Marsden Hospital between 1994 and
2001 who were diagnosed with metastatic breast cancer.
Treatment patterns and resource use
Information on usual treatment practice was collected from a panel
of cancer physicians (see Appendix for more detail). A survey
instrument (questionnaire) was designed that distinguished among
four predefined treatment phases following the occurrence of
metastasis (Figure 1): (1) active treatment; (2) follow-up after
active treatment until disease progression; (3) active supportive
care after disease progression; (4) end-of-life care.
It was assumed that following diagnosis of metastatic breast
cancer, patients received active treatment in the form of endocrine
therapy and/or chemotherapy. Active treatment included first- and
second-line treatment and, in some cases, third- and fourth-line
treatment. For those who received endocrine therapy, treatment
continued until disease progression. Thereafter, second-line
hormone therapy, chemotherapy, or supportive care would be
offered. For those patients who received chemotherapy, a varying
number of treatment cycles would be administered according to
the agent used and the treatment response. Patients would be
monitored until disease progression. Standard chemotherapeutic
agents could have been replaced by trastuzumab, either alone or in
combination with a taxane or vinorelbine. Following disease
progression, second-line chemotherapy or supportive care would
be offered.
Information on the use of radiotherapy and bisphosphonates
during the active-treatment phase was also collected in the survey.
Several resource elements were listed in each category within each
treatment phase (Table 1).
Participating physicians were asked to indicate the length of
each treatment phase and the percentage of patients receiving each
type of care. They were also asked to make additions or deletions
of care elements to reflect differences in the current management
and treatment of stage IV breast cancer patients at their
institutions. Where dosage calculations required body surface
area or weight, 1.7m
2 or 70kg per patient, respectively, was
assumed.
The median was selected a priori as the chosen summary
measure of resource consumption, with the only exception being
the choice of mutually exclusive resource items within treatment
groups (ie, where only one drug or procedure, such as a
chemotherapeutic regimen, can be chosen at any one time), for
which the mean resource consumption was calculated.
Drug costs were based on the British National Formulary (2000),
and unit costs for other resources were obtained from the
MEDTAP Database of International Unit Costs (2001). Unit costs
in the database aim to represent the social opportunity cost of
health care resources. Medical staff salaries, overheads as well as
equipment costs were included in the calculations. Where
necessary, the National Health Service Hospital and Community
Inflation Index (PSSRU, 2001) was used to convert these costs to
year 2000 prices. Only direct medical costs were included in the
cost-of-illness analysis.
Cost-of-illness calculation
It was assumed that endocrine therapy, chemotherapy, or
trastuzumab therapy (with or without chemotherapy) would be
administered only sequentially, but that radiotherapy and treat-
ment with bisphosphonates may be given concomitantly with any
of the above treatments. Average monthly costs per patient were
calculated, using this assumption together with the average
treatment lengths indicated by the panel, for a combined active-
treatment phase (weighted average of the endocrine therapy and
chemotherapy), supportive-care phase, and end-of-life care phase.
These monthly costs were then combined with the median survival
figure – assuming that all the patients must pass through the
supportive-care phase and end-of-life care phase – to obtain the
average lifetime cost per patient. This figure was then multiplied
by the estimated incidence of stage IV at presentation breast
cancer for an estimate of the overall economic burden for this
segment of the breast cancer population. As median survival is
short, discounting future costs was deemed unnecessary. The
robustness of the results was tested in a multivariate sensitivity
analysis using Crystal Ball
s software (Decisioneering, Inc., Crystal
Ball 2000, Standard Edition).
1. Endocrine therapy scenario
3. Active 
supportive
care
4. End-of-life
care
1. Active chemotherapy
Chemotherapy scenario
2. Follow-up
Disease
progression
Diagnosis of
metastatic disease Death
Figure 1 The four treatment phases for stage IV breast cancer: (1) active
treatment (endocrine therapy and/or chemotherapy, including multiple
cycles); (2) follow-up treatment until disease progression; (3) active
supportive care after disease progression; and (4) end-of-life care. (Second-,
third-, and further-line active-treatment cycles and subsequent follow-up
may also be elected after an instance of disease progression (indicated by
backward arrows)).
Table 1 Categories of resource use
In active-treatment phase In all treatment phases
K Endocrine therapy K Palliative radiotherapy
K Chemotherapy K Medications
J Monotherapy K Special interventions
J Combination therapy K Investigations, procedures
K Trastuzumab K Laboratory tests
K Bisphosphonates K Hospitalisations, hospice visits
K Radiotherapy K Outpatient visits, other services
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lRESULTS
Incidence
Reported annual incidence of stage IV at presentation breast
cancer from four English registries and the Scottish Cancer
Registry is shown in Table 2. These five registries recorded
more than 17000 new cases of breast cancer in 1998 and 1999.
The proportion of breast cancer patients presenting with meta-
static disease ranged from 3.64% (West Midlands) to 6.21%
(Northern & Yorkshire) of all incident cases. Each country’s
average proportion was used separately to estimate the total
incidence of stage IV at presentation cases in England and
Scotland, and the overall (combined English and Scottish data;
Table 2) average proportion was used to estimate the total
incidence of stage IV at presentation cases in Wales and Northern
Ireland (Table 3). With these calculations, the total number of
newly diagnosed patients in the UK with stage IV breast cancer was
estimated to be 2070 (Table 3).
Treatment patterns and resource use
In total, 21 questionnaires regarding treatment patterns and
resource use were mailed to members of the cancer physician
panel; 17 (81%) of these were completed and returned. The
composition of the panel reflected the specialties of clinicians
responsible for treating patients with stage IV breast cancer.
Participants included consultants from the fields of Medical
Oncology, Clinical Oncology, and cancer research, and they
represented a range of hospitals in the north and south of England
(see Appendix). Treatment patterns and treatment-associated
average monthly costs from survey results are summarised in
Table 4.
According to our results, 70% of patients receive some form
of endocrine therapy during the active-treatment phase. The
majority of patients receive either tamoxifen (41%) or an
aromatase inhibitor (anastrozole, 38%; letrozole, 8%); 60% of
patients are treated with chemotherapy, and 5% receive trastuzu-
mab. Anthracyclines (alone or in combination) are the most
frequently used chemotherapeutic agents (administered to 55%
of chemotherapy patients), whereas approximately 41% of
chemotherapy patients receive some form of antimetabolite,
usually as part of a combination therapy. Taxanes are administered
to 17% of patients, with docetaxel being the first option.
Radiotherapy is administered to 35% of patients with metastatic
breast cancer. It may be used to treat locally recurrent disease
or to palliate bone, brain, or spinal cord lesions. Bisphosphonates
have an important role in the treatment of osteolytic lesions,
hypercalcaemia, and bone pain associated with skeletal metas-
tases. Half of the population of patients with metastatic breast
cancer are treated with bisphosphonates. In terms of resource use
and apart from the main therapeutic agents, scans, laboratory
tests, and outpatient visits to monitor disease development
represent the largest items of care during the active-treatment
phase (Table 4).
In the supportive-care phase, the emphasis shifts from active
therapies to treatments aimed at alleviating pain and other
symptoms. The frequency of blood transfusions and other
special interventions increases. The greatest change in terms of
resource use can be observed in the increased numbers of
hospitalisations, hospice stays, and outpatient visits. During the
active-treatment phase, these represent 23.4% of average monthly
costs; in the supportive-care phase, they represent approximately
61% of average monthly costs. This trend continues into the end-
of-life phase, during which actual medical treatment is almost
entirely restricted to administering medication to alleviate
symptoms of the disease. Most resource use at this time (96%) is
associated with hospitalisations, hospice stays, and outpatient
visits. According to survey results, 20% of patients are hospitalised
(average length of stay, 7 days), and 70% of patients receive care
in a hospice (30%, day visits; 40%, average of five overnight
stays) (Table 4).
Cost-of-illness calculation
Monthly costs for the active-treatment phase and the follow-up
phase were combined according to the distribution of treatments
indicated in the survey (each with or without follow-up between
end of treatment and disease progression) in order to obtain an
estimate of average per-patient monthly costs for the entire
population of patients. The average monthly costs for each
treatment phase are summarised in Table 5.
According to Royal Marsden Hospital data, the median survival
for patients diagnosed with stage IV breast cancer is 18 months. In
the absence of reliable survival estimates for other UK regions, this
figure was used to calculate lifetime costs per patient for the entire
UK; thus, treatment for metastatic breast cancer was estimated to
cost d12502 (95% confidence interval (CI); d9008–d16701) over
the lifetime of each patient. Translating this individual cost to the
population level, it was calculated that treating all patients in
England that present with stageIV breast cancer in 1 year costs
approximately d22 million, and treating all patients throughout the
UK costs approximately d26 million (Table 6).
In the sensitivity analysis, the variable for incidence of stage IV
at presentation breast cancer was allowed to follow a normal
distribution, with the 5% tile being 1440 cases per annum
(assuming that all of the UK experiences the lower incidence rate
reported by the West Midlands registry), and the 95% tile being
2456 cases (assuming that all of the UK experiences the higher
incidence rate reported by the Northern & Yorkshire registry)
(Table 2). The length of each predefined treatment phase and its
Table 2 Incidence of de novo stage IV breast cancer in four English
regions and in Scotland
a
Region Year
Incidence
of breast
cancer
Incidence of
stage IV at
diagnosis
Proportion
diagnosed
with
stage IV (%)
Northern & Yorkshire 1998 3964 246 6.21
East Anglia 1998 1834 98 5.34
Thames (London region) 1999 4236 251 5.93
West Midlands 1999 3573 130 3.64
English registries,
combined
5.33
Scotland 1998 3523 155 4.40
Overall 5.14
aAs reported by four English registries and the Scottish Cancer Registry (see
Appendix). Bold values represent the total values.
Table 3 Estimated incidence of de novo stage IV breast cancer in the UK
Region Year
Incidence
of breast
cancer
Proportion
diagnosed
with
stage IV (%)
a
Incidence
of stage IV
breast cancer
England 1998 32908
b 5.33 1753
Scotland 1998 3523
c 4.40 155
Wales 1997 2270
d 5.14 117
Northern Ireland 1996 873
d 5.14 45
UK 39574 2070
aSee Table 2.
bOffice for National Statistics (2002).
cScottish Cancer Registry (1998).
dOffice for National Statistics (2001). Bold values represent the total values.
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responses from the 17 clinicians participating in the resource use
survey. The median survival was allowed to follow a normal
distribution, with a mean of 18 months and a standard deviation of
3 months. The resulting 95% CI for annual costs is reported
in Table 6.
DISCUSSION
The present study estimated the direct cost of lifetime treatment of
all patients in the UK presenting with stage IV breast cancer within
a given year at approximately d26 million. This undoubtedly
underestimates the total economic burden that stage IV breast
cancer places on the health-care system for two reasons. First,
cancer registries are not always able to provide complete
information: registry databases do not include all patients with
cancer, nor do they include the stage at diagnosis for every patient
registered. For example, the stage at diagnosis was unknown in
Table 4 Treatment patterns and associated costs for stage IV breast cancer in the UK
Resource category (%)
Major resource items
within category (%)
a
Average monthly
cost per patient
within category (d)
Percentage of monthly
costs per patient
(within phase) (%)
(a) Active-treatment phase and follow-up phase
Active-treatment phase
Endocrine treatment (70%)
b Tamoxifen (41%)
c
Aromatase inhibitors (52%) 52.17 3.1
Chemotherapy (60%)
b Combination chemotherapy (45%)
Single agent (55%)
403.46 20.7
Trastuzumab (5%)
b Alone (68%)
c
Combination(32%)
1899.34 8.1
Bisphosphonates (50%)
b 179.95 10.4
Radiotherapy (35%)
b Four fractions per annum 19.78 0.8
Medication for supporting: Chemotherapy 54.09 3.0
Endocrine therapy 11.91 0.7
Special interventions 29.25 3.4
Scans and laboratory tests 227.63 26.3
Hospitalisations Endocrine patients (10%) 15.63 0.9
Chemotherapy patients (20%) 56.25 3.1
Outpatient visits Specialist visit (100%) 166.79 19.3
Day case (50%)
Follow-up phase
Medication 9.84 6.3
Scans and laboratory tests 62.91 40.4
Outpatient visits Specialist visit (100%) 82.90 53.3
Day case (18%)
GP (40%)
District nurse (30%)
(b) Supportive care and end-of-life care
Supportive-care phase
Radiotherapy Average 0.3 fractionsmonth 17.80 2.5
Medication 62.90 9.3
Special interventions 101.66 15.1
Scans and laboratory tests 77.77 11.6
Hospitalisations 42% 157.40 23.4
Outpatient visits Specialist (90%) 255.20 37.9
MacMillan nurse (65%)
District nurse (50%)
End-of-life phase
Radiotherapy Average 0.1 fraction 5.93 0.5
Medication 39.86 3.0
Laboratory tests 1.75 0.1
Hospitalisations 20% 395.59 30.0
Hospice stays 70% 498.66 37.9
Outpatient visits Oncologist (20%) 374.17 28.4
District nurse (60%)
MacMillan nurse (75%)
Palliative care physician (50%)
aOnly the major treatment items (those received by 45% of patients) within each resource category are listed.
bPercentage of total patients who received this category of
treatment.
cPercentage of those patients receiving this category of treatment who received this specific treatment.
Table 5 Monthly costs of stage IV breast cancer per patient
Treatment phase
Estimated length
(months)
Average monthly
cost per patient (d)
Active
a 13.53 679
Supportive care 4.00 675
End-of-life 0.47 1316
b
aActive-treatment and follow-up phases combined.
bCost per phase.
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l44% of the new breast cancer registrations made in 1999 by the
Thames Cancer Registry for residents of the London region.
Therefore, a certain number of stage IV patients might not have
been registered at all or might have been registered but not
classified as having stage IV disease. Second, about 50% of those
patients diagnosed (and registered) with an earlier disease stage
will later develop metastases (Blum, 2001). However, disease
progression is not documented by the cancer registries, therefore,
the estimates are necessarily limited to the population of patients
with stage IV disease at the time of breast cancer diagnosis. This
figure is still important economically and is useful to know for
helping to develop increased awareness, better screening/detection
and preventative measures especially in high-risk groups.
As an exploratory analysis, we also estimated the overall number
of patients with stage IV breast cancer. Using incidence and
survival information from the Royal Marsden Hospital database,
assuming that 50% of patients will develop stage IV disease 18
months (the median survival for those diagnosed with stage IV
disease) before death, and assuming no changes in incidence of
breast cancer, the prevalence of stage IV breast cancer was
estimated at about 29500 once steady state is reached. The crude
estimate of annual cost of treatment for metastatic breast cancer is
then over d245 million.
Prospectively observed treatment patterns for patients with
stage IV breast cancer would be preferable to estimates derived
from surveying a cancer physician panel. Although there is
reasonable geographical spread in selected physicians, the selec-
tion was random. The panel included physicians with breast cancer
as their main interest, but it was a general panel reflecting the
multidisciplinary practice for breast cancer. Physicians were asked
to describe treatment practices in their hospital, not their own
views, and there was no incentive to answer in a particular way or
in favour of a particular treatment, but there is potential for bias as
only those with enough time to complete the lengthy questionnaire
participated. Nonetheless, in the absence of observed treatment
patterns, the estimates presented here provide information on the
major resource items used and the associated treatment costs for
patients with stage IV breast cancer.
We identified two other studies that calculated lifetime costs of
stage IV breast cancer in the UK (Richards et al, 1993;
Wolstenholme et al, 1998). Richards et al analysed the medical
records of 50 patients with advanced breast cancer at Guy’s
Hospital Oncology Unit. The median duration of advanced disease
was 17 months and the mean cost of treatment per patients was
calculated to be d7620 (range, d317–d27860). Wolstenholme et al
took a random sample of the case notes of 137 patients diagnosed
with breast cancer in 1991 from the Trent Cancer Registry. Only six
of these patients were diagnosed with stage IV disease, and the
range of the cost estimate was very wide. The mean total cost of
diagnosis and treatment for stage IV disease over 4 years – d6591
in 1991 prices – was significantly higher than that for any of the
earlier stages. Dolan et al (1999) used this information to calculate
secondary care costs for breast cancer in the UK. They estimated
that there were 1456 women with stage IV disease in 1995–1996,
costing the National Health Service a total of almost d13 million.
Inflating these costs to prices in the year 2000 using the National
Health Service Hospital and Community Inflation Index (PSSRU,
2001) brings the cost reported by Richards et al to d9555 (range,
d397–d34935) and the cost reported by Wolstenholme et al to
d9002 (range, d1276–d11904). These figures are comparable to
our results. A number of factors can explain the slight difference:
for example, the above estimates did not include the costs of
general practitioner visits or palliative care, both of which we
observed to play an important role, especially in the last two
treatment phases; furthermore, a small samples may not be
representative of a population with considerable survival and
treatment variability.
Although metastatic breast cancer is considered incurable,
survival may range from a few months to several years. Analysis
of a series of patients with recurrent disease indicates that survival
is related to the sites of metastasis. Visceral recurrences were
associated with shorter survival; patients with bone and soft tissue
metastases had a better prognosis (Leone et al, 1988; Perez et al,
1990). A multivariate analysis of prognostic factors for survival in
439 women with recurrent breast cancer showed that the following
factors were associated with shorter survival from the time of the
first recurrence: site of recurrence; four or more axillary lymph
nodes involved at initial diagnosis; negative oestrogen receptor
status; and disease-free interval (time from diagnosis of primary
tumour to recurrence) of less than 60 months (Insa et al, 1999).
The dominant site of metastasis was also an important determi-
nant for response to treatment and survival in a Cox proportional
hazard model analysis of 371 patients (Nomura, 1998). Having a
single bone lesion, rather than multiple bone lesions or additional
visceral involvement, seems to be associated with the best outlook
for survival. Durr et al (2002) followed 70 patients with breast
cancer who were surgically treated for bone metastasis. For the
entire group (including those with one or multiple bone lesions
and 32 patients with additional visceral involvement), the 5-year
survival rate was 13%, whereas patients with solitary bone lesions
had a 39% chance of 5-year survival.
Treatment of metastatic breast cancer is growing increasingly
complex with the recent introduction of several new treatment
options. Since these novel therapies come at a relatively high price,
it is not surprising that they feature prominently on the agenda of
the National Institute for Clinical Excellence (NICE). In 2001, NICE
recommended the use of the taxanes, docetaxel and paclitaxel, as
an option for the treatment of patients with advanced breast cancer
for whom cytotoxic chemotherapy (including an anthracycline)
has failed or is judged inappropriate (NICE, 2001). In 2002, NICE
also recommended that trastuzumab be available for women with
advanced breast cancer and high levels of HER2. The recommen-
dation is to administer trastuzumab either in combination with
paclitaxel for women who have not had chemotherapy and for
whom anthracycline treatment is not appropriate, or as mono-
therapy for women who have had at least two chemotherapy
treatments for metastatic breast cancer. The previous therapy must
have included at least an anthracycline and a taxane, if
appropriate; for patients sensitive to oestrogen, it should also
have included hormonal therapy (NICE, 2002a). For combination
therapy, trastuzumab is currently licensed for use only with
paclitaxel, but our survey showed off-label use with docetaxel and
with vinorelbine. However, a recent comprehensive audit of
availability of breast cancer drug shows huge variations in access
across the UK (CancerBACUP, 2003). Nationally, only around 33%
of women who may benefit from trastuzumab are receiving it. This
finding may explain why trastuzumab treatment was indicated for
only 5% of patients in our treatment survey. This figure is likely to
rise as changes in treatment patterns lead to more patients
receiving relatively more expensive treatments. Greater use of
trastuzumab and the taxanes will increase the overall cost of
Table 6 Population-level cost of stage IV breast cancer in the UK
Region
Annual incidence
of stage IV
breast cancer
Annual cost per
population (d)
England 1753 21920115
Scotland 155 1937899
Wales 117 1457883
Northern Ireland 45 560675
UK total 2070 25876572
(95% CI: 13316695–38936650)
Bold values represent the total values.
Cost of stage IV at presentation breast cancer
E Rema ´k and L Brazil
81
British Journal of Cancer (2004) 91(1), 77–83 & 2004 Cancer Research UK
C
l
i
n
i
c
a
ltreatment for metastatic breast cancer in the UK. According to
data provided in the industry submission during the NICE
appraisal procedure, trastuzumab is likely to add d15.8 million
to the health-care budget. Assessments of other therapies for
advanced cancer are in progress: a technology guidance appraisal
of vinorelbine and capecitabine use for advanced breast cancer was
recently published by NICE (NICE, 2002b, 2003).
For women with oestrogen-receptor-positive breast cancer,
tamoxifen has long been the treatment of choice. A relatively
new strategy for blocking oestrogen action in postmenopausal
women is aromatase inhibition (i.e., blocking oestrogen synthesis).
Aromatase inhibitors are licensed for second-line treatment for
those not responding to, or otherwise inappropriate for, tamoxifen
therapy. However, clinical evidence is emerging that the aromatase
inhibitors letrozole and anastrozole may be similar or superior to
tamoxifen for first-line treatment for metastatic breast cancer
(Bonneterre et al, 2000; Nabholtz et al, 2000; Mouridsen et al,
2001). Notably, the monthly cost of anastrozole or letrozole is
more than 10 times that of tamoxifen. Increased use of these agents
raise the costs of treatment for metastatic breast cancer
considerably, and costs are likely to increase further as their role
in therapy continues to grow.
CONCLUSION
Information about the incidence of advanced breast cancer is
scarce; additionally, considerable variability exists in the treatment
patterns and survival time for patients with stage IV breast cancer,
depending on factors such as the site and number of metastases
and the individual physician’s approach to therapy. The present
study provides estimates of the incidence of newly diagnosed
metastatic breast cancer in the UK and of the cost of treatment of
these cases. Stage IV breast cancer imposes a substantial economic
burden in the UK, and this burden should be taken into
consideration when developing strategies such as awareness
programmes, screening, and prevention to reduce the incidence
of this disease.
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In order to inform on treatment patterns and costs associated with
metastatic breast cancer, a panel of cancer clinicians was consulted
with the help of a survey instrument. Physicians were randomly
selected from the Medical Directory based on their listed specialty.
Year 4–5 Specialist Registrars (i.e. not Junior Registrars) or
Consultants were invited, who see 50–100 breast cancer cases per
month. A maximum of three physicians were accepted from each
hospital. A total of 56 clinicians were invited to participate, of
whom 35 (63%) declined due to other work-related responsi-
bilities. 21 questionnaires were posted.
An initial survey instrument was developed that included the
core components of care associated with each treatment phase.
Professor Michael Lind, Consultant Oncologist at The Princess
Royal Hospital, Sutton acted as a consultant on both the layout and
contents of the questionnaire, and the final survey instrument was
developed based on his comments. The panel was asked to think of
a group of ‘typical’ patients and provide a description of the
treatment these patients would receive in their institution. The
medical history and health status of a typical patient was described
before each phase. The aim was to gather information on usual
clinical practice as opposed to best practice, as usual practice is
more informative for determining actual cost of treatment.
Physicians were paid for the time only, receiving d360 for approxi-
mately 3h of work. No additional remuneration was offered. Physi-
cians were not asked to comment on specific drugs or procedures.
Members of the cancer physician panel
Dr A Abdussalam (Airedale General Hospital, Keighley); Dr T
Ahmed (Institute for Cancer Research, London); Dr J Brock
(Clattenbridge Centre for Oncology NHS Trust, Merseyside); Dr R
Burcombe (Mount Vernon Hospital, Middlesex); Dr DM Carnell
(Mount Vernon Hospital, Middlesex); Dr A Chalmers (Gray Cancer
Institute, Middlesex); Dr S Cleator (Institute for Cancer Research,
London); Dr M Clemons (Christie Hospital, Manchester); Dr D
Dodwell (Cookridge Hospital, Leeds); Dr D Fairlamb (New Cross
Hospital, Wolverhampton); Dr I Fernando (University Hospital
Birmingham NHS Trust, Birmingham); Dr J Larkin (Royal
Marsden Hospital, Surrey); Dr Nihal Shah (Royal Marsden
Hospital, London); Dr A Sibtain (Mount Vernon Hospital,
Middlesex); Dr JA Stewart (Northampton General Hospital,
Northampton).
Cancer registries
East Anglian Cancer Registry; Merseyside and Cheshire Cancer
Registry; North Western Cancer Registry; Northern and Yorkshire
Cancer Registry; Oxford Cancer Intelligence Unit; South and West
Cancer Intelligence Service; Thames Cancer Registry; Trent Cancer
Registry; West Midlands Cancer Intelligence Unit; Welsh Cancer
Intelligence and Surveillance Unit; Scottish Cancer Registry;
Northern Ireland Cancer Registry.
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